FDA Approves SKYRIZI® for Ulcerative Colitis, Expanding AbbVie’s IBD Portfolio AbbVie announced that the U.S. FDA has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis. This…
Lilly’s Commitment to Safe Use of Mounjaro® and Zepbound® Lilly is dedicated to improving lives for people with diabetes and obesity through innovative medications like Mounjaro® and Zepbound®. Guided by…
Actylis, a prominent global manufacturer and sourcing expert specializing in critical materials and performance ingredients for life sciences and specialty chemicals, has appointed Scott Thomson as its new Chief Executive…
Marinus Pharmaceuticals, a company focused on developing innovative therapeutics for seizure disorders, has announced topline results from the Phase 3 RAISE trial (NCT04391569). This double-blind, randomized, placebo-controlled study assessed the…
Takeda Releases Phase 3 Topline Results for Soticlestat (TAK-935) in Dravet Syndrome and Lennox-Gastaut Syndrome OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE The SKYLINE trial (TAK-935-3001) was a multicenter, randomized,…
UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van…
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today the latest efficacy and safety updates from the Phase 1/2 trial of SAR443579/IPH6101 (SAR’579), a CD123 targeting NKp46/CD16-based Natural Killer…
Celltrion Unveils Positive Phase III Results of CT-P47 Biosimilar for Rheumatoid Arthritis at EULAR 2024 Celltrion has revealed encouraging findings from its Phase III study of CT-P47, a biosimilar referencing…
Celltrion today presented positive Phase III data for CT-P47, a biosimilar referencing RoActemra® in patients with moderate-to-severe rheumatoid arthritis (RA), at the Annual European Congress of Rheumatology (EULAR) 2024. The…
Genentech, part of the Roche Group, announced significant results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) with GemOx (R-GemOx) in…
BeiGene Presents New Data on BRUKINSA® and Venetoclax Combination for High-Risk CLL/SLL at EHA2024 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of…
Sparrow Pharmaceuticals presented data from an ongoing Phase 2 trial of the HSD-1 inhibitor clofutriben (SPI-62) and prednisolone for polymyalgia rheumatica (PMR) at EULAR 2024 in Vienna, Austria (June 12-15).…